Welcome to our dedicated page for Senti Bioscience SEC filings (Ticker: SNTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Overview
Senti Biosciences (SNTI) is a clinical-stage biotechnology company that harnesses the power of synthetic biology to develop advanced cell and gene therapies. With a focus on oncology and other unmet medical needs, the company has pioneered a proprietary Gene Circuit platform designed to program off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells. This cutting-edge technology enables precise targeting of cancer cells while sparing healthy cells, potentially offering a transformative approach to treating diseases with limited therapeutic options.
Technology and Innovation
Senti Biosciences stands out with its innovative use of Gene Circuits, a technology that integrates synthetic biology and advanced gene editing techniques. By incorporating logic gates (such as OR and NOT mechanisms) into the design of CAR-NK cells, the company is able to finely tune therapeutic activity. This intelligent system enhances the specificity of cell therapies, ensuring that cancer cells are eliminated while preserving essential healthy tissues.
Therapeutic Platforms
The company’s pipeline comprises wholly-owned programs that utilize off-the-shelf CAR-NK cells engineered via its Gene Circuit platform. Among these, its product candidates are designed to address significant challenges in both liquid and solid tumors. The adaptive nature of the platform allows for tailored approaches in treating hematologic malignancies like acute myeloid leukemia (AML) and solid tumors such as hepatocellular carcinoma (HCC). Through rigorous preclinical studies, the potential of these therapies has been demonstrated by their selective cytotoxic effects and improved control over therapeutic payload expression.
Clinical Development and Strategic Collaborations
Senti Biosciences is advancing multiple clinical programs that highlight its commitment to innovation in cell therapy. Its clinical-stage trials are designed to evaluate the safety, tolerability, and initial efficacy of its gene circuit-enabled therapies. In parallel, the company has established strategic collaborations with other biotechnology firms and research institutions to accelerate clinical development and expand its technological capabilities. These alliances not only foster shared expertise but also enhance the scalability and robustness of its therapeutic design platform.
Market Position and Value Proposition
Positioned at the intersection of synthetic biology and immunotherapy, Senti Biosciences is addressing critical limitations of conventional cancer treatments. By leveraging a proprietary platform that offers enhanced precision, safety, and adaptability, the company is poised to impact the field of cell and gene therapy in a significant manner. Its focus on developing off-the-shelf therapies aims to streamline manufacturing processes and reduce variability, thereby offering potential operational advantages in the competitive biotechnology landscape.
Scientific Expertise and Research Acumen
The company is driven by a multidisciplinary team of engineers, scientists, and entrepreneurs who bring a wealth of experience in synthetic biology, gene editing, and clinical research. This blend of expertise underpins the rigorous development process and enables Senti Biosciences to tackle complex therapeutic challenges with scientific rigor. The integration of industry-specific terminology and methods in its research demonstrates a high level of authority and trustworthiness in the rapidly evolving field of biopharmaceuticals.
Commitment to Quality and Safety
In every stage of its research and development, Senti Biosciences adheres to stringent quality and regulatory standards. The design of its Gene Circuit technology is tailored not only to enhance therapeutic efficacy but also to significantly reduce potential off-target effects. This careful balance of innovation and safety is central to the company’s commitment to improving patient outcomes, particularly for those with incurable diseases.
Conclusion
Through its groundbreaking work in synthetic biology and advanced cell therapy, Senti Biosciences exemplifies a modern approach to combating cancer and other severe diseases. By focusing on a versatile and scalable platform, the company continues to build its reputation as a trusted innovator in the biotechnology space. Its comprehensive strategy—encompassing technology development, strategic collaborations, and rigorous clinical evaluation—positions it as a vital contributor to the evolution of precision medicine.
Senti Biosciences director Fran Schulz received a stock option grant on June 25, 2025. The grant consists of 21,950 options to purchase common stock at an exercise price of $2.05 per share.
Key terms of the option grant:
- Exercise price: $2.05 per share
- Expiration date: June 24, 2035
- Vesting schedule: 100% vests at earlier of (i) first anniversary of grant date or (ii) 2026 Annual Meeting
- Vesting contingent on continued service through applicable date
The Form 4 was filed by Robert Cutler as attorney-in-fact on June 27, 2025. This transaction represents standard non-employee director equity compensation and aligns the director's interests with shareholders through long-term stock ownership potential.
Form 4 filing reveals that Donald F. Tang, Director at Senti Biosciences (SNTI), received a stock option grant on June 25, 2025. The derivative securities transaction details include:
- Granted 21,950 stock options to purchase common stock
- Exercise price set at $2.05 per share
- Options expire on June 24, 2035
- Vesting schedule: 100% vests at earlier of: - First anniversary of grant date - Date of 2026 Annual Meeting
Vesting is contingent on Tang's continued service through the applicable vesting date. The transaction was reported through an attorney-in-fact, Robert Cutler, on June 27, 2025. This equity compensation aligns with standard director compensation practices and aims to align the director's interests with shareholders.
FAQ
What is the current stock price of Senti Bioscience (SNTI)?
What is the market cap of Senti Bioscience (SNTI)?
What is the core focus of Senti Biosciences?
How does the Gene Circuit platform work?
What types of diseases does Senti Biosciences target?
What makes Senti Biosciences' approach unique in the biotechnology space?
What are CAR-NK cells and why are they important?
How does Senti Biosciences ensure safety in its therapies?
What role do strategic collaborations play at Senti Biosciences?
How does Senti Biosciences position itself in the competitive market?
